Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
Eric E. Swayze(Ionis Pharmaceuticals (United States)), and C. Frank Bennett(Ionis Pharmaceuticals (United States)), Edward V. Wancewicz(Ionis Pharmaceuticals (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States)), Michael T. Migawa(Ionis Pharmaceuticals (United States)), Gene Hung(Ionis Pharmaceuticals (United States)), Andrew Siwkowski(Ionis Pharmaceuticals (United States)), Tadeusz K. Wyrzykiewicz(Ionis Pharmaceuticals (United States))
Cited by 461
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
|Hepatology|2007|1k
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
|Journal of Biological Chemistry|1993|770